Last reviewed · How we verify
Ciclesonide & Levocetirizine
Ciclesonide is an inhaled corticosteroid that reduces airway inflammation, while levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.
Ciclesonide is an inhaled corticosteroid that reduces airway inflammation, while levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis with asthma or allergic airway disease.
At a glance
| Generic name | Ciclesonide & Levocetirizine |
|---|---|
| Also known as | Omnaris nasal spray, XYZAL |
| Sponsor | Handok Inc. |
| Drug class | Inhaled corticosteroid + selective H1-receptor antagonist combination |
| Target | Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
Ciclesonide works by binding to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Levocetirizine competitively blocks H1 histamine receptors on mast cells and other immune cells, preventing histamine-induced allergic symptoms such as itching, sneezing, and rhinitis. Together, they provide dual anti-inflammatory and antihistamine effects for allergic airway disease.
Approved indications
- Allergic rhinitis with asthma or allergic airway disease
Common side effects
- Headache
- Pharyngitis
- Tremor
- Somnolence
- Dysphonia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |